The Center for Law, Health & Society faculty are well-regarded teachers and scholars, but they also seek to have an impact beyond the world of academia. A sampling of their activities over the last several months provides a glimpse at the ways in which faculty members bring their research and expertise to others.
Sylvia Caley (M.B.A. ’86, J.D. ’89), who brings her own interprofessional training (in nursing, law, and business) to her work in the Health Law Partnership (HeLP), commonly reaches across the professions, most recently as an invited speaker on legal services to address the social determinants of health and congenital heart disease at the American Heart Association conference in New Orleans.
Yaniv Heled and Leslie Wolf recently presented at a continuing legal education program at the Georgia Capitol organized by the Georgia Senate Research Office. Heled spoke about the state of autonomous vehicles regulation, and Wolf about laws about end of life decision-making.
Paul Lombardo applies his research in eugenics as a member of the Advisory Board and a consultant for the Eugenic Rubicon, a University of Michigan project to put data about sterilization survivors online. He also is consulting on the National Institute of Health and Hasting Center on a project to assess the ethical significance of the next generation prenatal testing technologies.
Jonathan Todres brings his expertise in human rights, especially children’s rights, and child trafficking to his service on the Georgia Asylum and Immigration Network (GAIN) Board and as a child rights advisor on the board of advisors of ECPAT-USA, which focuses on ending child slavery.
Patti Zettler’s experience with FDA law informs her work as a consultant for the National Academies of Sciences, Engineering, and Medicine’s Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse. The committee is developing a report that will inform the U.S. Food and Drug Administration (FDA) as to the state of the science regarding prescription opioid abuse and misuse and will make recommendations on the options available to FDA to address the prescription opioid overdose epidemic.